Hepatitis C virus associated glomerulopathies.

Area of Science:

• Nephrology
• Hepatology
• Immunology

Background:

• Hepatitis C virus (HCV) infection is a systemic disease with significant extrahepatic manifestations, particularly affecting the kidneys.
• HCV infection is linked to an increased risk of end-stage renal disease and poorer outcomes after kidney transplantation.
• Various glomerulopathies, including membranoproliferative glomerulonephritis (MPGN) and membranous nephropathy, are associated with HCV.

Purpose of the Study:

• To review the spectrum of HCV-associated glomerulopathies and their clinical presentations.
• To discuss the therapeutic strategies for managing HCV-related kidney diseases and cryoglobulinemic renal disease.
• To highlight the importance of considering renal involvement in patients with HCV infection.

Main Methods:

• Review of existing literature on HCV-associated renal diseases.
• Analysis of clinical manifestations, histological findings, and treatment outcomes.
• Categorization of therapeutic approaches including antiviral, B-cell depletion, and immunosuppressive therapies.

Main Results:

• The most common HCV-associated glomerulopathy is MPGN type I, often linked to mixed cryoglobulinemia.
• Renal manifestations include proteinuria, hematuria, hypertension, and nephrotic syndrome.
• Treatment strategies are tailored to disease severity, ranging from antiviral therapy (pegylated interferon-α plus ribavirin) to potent immunosuppression (cyclophosphamide, rituximab, steroids, plasmapheresis).

Conclusions:

• HCV infection poses a significant threat to renal health, necessitating vigilant monitoring and timely intervention.
• Treatment decisions for HCV-associated glomerulopathies should be individualized based on proteinuria levels, renal function, and extra-renal complications.
• A multi-pronged therapeutic approach, combining direct antiviral effects with modulation of immune-mediated damage, is crucial for managing these complex conditions.